| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.049 | 0.2 |